NZ788380A - Treatment of pain - Google Patents
Treatment of painInfo
- Publication number
- NZ788380A NZ788380A NZ788380A NZ78838017A NZ788380A NZ 788380 A NZ788380 A NZ 788380A NZ 788380 A NZ788380 A NZ 788380A NZ 78838017 A NZ78838017 A NZ 78838017A NZ 788380 A NZ788380 A NZ 788380A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- parz
- signaling
- endosomal
- inhibits
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016901912A AU2016901912A0 (en) | 2016-05-20 | Treatment of Pain | |
| NZ748579A NZ748579A (en) | 2016-05-20 | 2017-05-19 | Treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ788380A true NZ788380A (en) | 2025-07-25 |
Family
ID=60324618
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ788380A NZ788380A (en) | 2016-05-20 | 2017-05-19 | Treatment of pain |
| NZ748579A NZ748579A (en) | 2016-05-20 | 2017-05-19 | Treatment of pain |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ748579A NZ748579A (en) | 2016-05-20 | 2017-05-19 | Treatment of pain |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190298743A1 (enExample) |
| EP (1) | EP3458062A4 (enExample) |
| JP (3) | JP2019516734A (enExample) |
| CN (1) | CN109152777A (enExample) |
| AU (3) | AU2017268039A1 (enExample) |
| CA (1) | CA3024719A1 (enExample) |
| EA (1) | EA201892672A1 (enExample) |
| MX (2) | MX395658B (enExample) |
| NZ (2) | NZ788380A (enExample) |
| WO (1) | WO2017197463A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086458A1 (en) * | 2017-12-20 | 2019-06-27 | Takeda Pharmaceutical Company Limited | Inhibitors of protease activated receptor-2 |
| US20240066027A1 (en) | 2020-12-03 | 2024-02-29 | Domain Therapeutics | Novel par-2 inhibitors |
| WO2023233033A1 (en) | 2022-06-03 | 2023-12-07 | Domain Therapeutics | Novel par-2 inhibitors |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025191185A1 (en) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
| US7541156B1 (en) * | 2000-03-01 | 2009-06-02 | Pasricha Pankaj J | Method of identifying antinociceptive compounds using protease activated receptor-2 |
| GB2426517A (en) * | 2003-11-21 | 2006-11-29 | Univ Newcastle Res Ass | Methods and agents for inhibiting dynamin-dependent endocytosis |
| CN1938013A (zh) * | 2003-11-21 | 2007-03-28 | 纽卡斯尔大学研究协会有限公司 | 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂 |
| CA2562266A1 (en) * | 2004-04-08 | 2005-10-20 | Jadolabs Gmbh | Tripartite conjugates containing a structure interacting with cell membrane rafts and their use |
| JP4896870B2 (ja) * | 2004-04-08 | 2012-03-14 | ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用 |
| WO2009034464A2 (en) * | 2007-09-12 | 2009-03-19 | Newcastle Innovation Limited | Indole related compounds with physiological activity |
| AR070911A1 (es) * | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| WO2013010218A1 (en) * | 2011-07-15 | 2013-01-24 | Freie Universität Berlin | Inhibition of clathrin |
| TW201602109A (zh) * | 2013-09-25 | 2016-01-16 | 維泰克斯製藥公司 | 作為ｐａｒ－２訊息傳遞路徑之抑制劑之咪唑并嗒 |
| CN115531553A (zh) * | 2015-12-22 | 2022-12-30 | 武田药品工业株式会社 | 内体g蛋白-偶联的受体的三部分调节剂 |
| AT518095B1 (de) * | 2015-12-30 | 2018-01-15 | Univ Wien Tech | Verfahren zur Herstellung von ionischen Flüssigkeiten auf Basis des Bistriflimid-Anions |
| CA3086458A1 (en) * | 2017-12-20 | 2019-06-27 | Takeda Pharmaceutical Company Limited | Inhibitors of protease activated receptor-2 |
-
2017
- 2017-05-19 CA CA3024719A patent/CA3024719A1/en active Pending
- 2017-05-19 CN CN201780031175.0A patent/CN109152777A/zh active Pending
- 2017-05-19 MX MX2018014135A patent/MX395658B/es unknown
- 2017-05-19 NZ NZ788380A patent/NZ788380A/en unknown
- 2017-05-19 EA EA201892672A patent/EA201892672A1/ru unknown
- 2017-05-19 US US16/303,023 patent/US20190298743A1/en active Pending
- 2017-05-19 WO PCT/AU2017/050469 patent/WO2017197463A1/en not_active Ceased
- 2017-05-19 NZ NZ748579A patent/NZ748579A/en unknown
- 2017-05-19 EP EP17798408.5A patent/EP3458062A4/en active Pending
- 2017-05-19 AU AU2017268039A patent/AU2017268039A1/en not_active Abandoned
- 2017-05-19 JP JP2018560846A patent/JP2019516734A/ja active Pending
-
2018
- 2018-11-16 MX MX2022011564A patent/MX2022011564A/es unknown
-
2022
- 2022-01-04 JP JP2022000286A patent/JP7441246B2/ja active Active
-
2023
- 2023-03-20 AU AU2023201732A patent/AU2023201732A1/en not_active Abandoned
-
2024
- 2024-02-16 JP JP2024022451A patent/JP2024073450A/ja active Pending
-
2025
- 2025-04-28 AU AU2025202933A patent/AU2025202933A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX395658B (es) | 2025-03-26 |
| JP2024073450A (ja) | 2024-05-29 |
| EP3458062A1 (en) | 2019-03-27 |
| AU2023201732A1 (en) | 2023-04-20 |
| CA3024719A1 (en) | 2017-11-23 |
| JP2022061998A (ja) | 2022-04-19 |
| JP2019516734A (ja) | 2019-06-20 |
| AU2025202933A1 (en) | 2025-05-15 |
| JP7441246B2 (ja) | 2024-02-29 |
| NZ748579A (en) | 2025-07-25 |
| CN109152777A (zh) | 2019-01-04 |
| AU2017268039A1 (en) | 2018-12-06 |
| EP3458062A4 (en) | 2020-01-15 |
| EA201892672A1 (ru) | 2019-04-30 |
| MX2022011564A (es) | 2023-06-15 |
| MX2018014135A (es) | 2019-06-17 |
| WO2017197463A1 (en) | 2017-11-23 |
| US20190298743A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023201732A1 (en) | Treatment of pain | |
| US7098204B2 (en) | Hymenialdisine or derivatives thereof in the manufacture of medicaments | |
| US20250235544A1 (en) | Tripartite Modulators of Endosomal G Protein-Coupled Receptors | |
| US9610358B2 (en) | Targeted pharmacological chaperones | |
| JP2007516434A (ja) | リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用 | |
| JP2012502884A (ja) | 選択的グリコシダーゼ阻害剤およびその使用 | |
| US20170275249A1 (en) | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase | |
| KR20220004068A (ko) | 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법 | |
| US6677376B1 (en) | Non-peptidic cyclophilin binding compounds and their use | |
| KR102543227B1 (ko) | 폐고혈압을 치료하기 위한 병용 요법 | |
| EP2004165A2 (en) | Synergistic combinations of anticancer agents for treating cancer | |
| US11919895B2 (en) | GPR183 antagonists for the treatment of pain | |
| EP1802297B1 (en) | Compositions and methods for treatment of disease caused by yersinia spp infection | |
| US10543282B2 (en) | Targeted peptide conjugates | |
| EP4221753A1 (en) | Compositions and methods of treating kidney disease and fibrosis | |
| US20200206299A1 (en) | Inhibitors of beta-arrestin-neurokinin 1 receptor interactions for the treatment of pain | |
| US11020378B2 (en) | Compounds, compositions and methods for treating insulin resistance | |
| BR112018012425B1 (pt) | Composto tripartido, e, composição farmacêutica | |
| CA2728366A1 (en) | Small molecule correctors of deltaf508 cftr trafficking |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ENDOSOME THERAPEUTICS, INC., US Effective date: 20240617 |
|
| PSEA | Patent sealed |